Nature Communications (Oct 2021)

FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth

  • Mengmeng Niu,
  • Jing Xu,
  • Yang Liu,
  • Yuhuang Li,
  • Tao He,
  • Liangping Ding,
  • Yajun He,
  • Yong Yi,
  • Fengtian Li,
  • Rongtian Guo,
  • Ya Gao,
  • Rui Li,
  • Luping Li,
  • Mengyuan Fu,
  • Qingyong Hu,
  • Yangkun Luo,
  • Chunyan Zhang,
  • Kewei Qin,
  • Jianqiao Yi,
  • Shuhan Yu,
  • Jian Yang,
  • Hu Chen,
  • Liang Wang,
  • Zhonghan Li,
  • Biao Dong,
  • Shiqian Qi,
  • Liang Ouyang,
  • Yujun Zhang,
  • Yang Cao,
  • Zhi-Xiong Jim Xiao

DOI
https://doi.org/10.1038/s41467-021-26222-x
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 15

Abstract

Read online

Aberrant EGFR activation is commonly found in non-small cell lung cancer (NSCLC). Here the authors show that E3 ubiquitin ligase FBXL2 targets EGFR and EGFR tyrosine kinase inhibitor (TKI)-resistant mutants for proteasome-mediated degradation to inhibit EGFR-driven NSCLC growth and TKI resistance.